CPC C07K 16/2809 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); C07K 16/3092 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/572 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01)] | 19 Claims |
1. A bispecific antibody construct comprising:
a first domain comprising an antibody which binds to MUC17, wherein the antibody comprises a CDR-H1 as set forth in the amino acid sequence of SEQ ID NO: 176, a CDR-H2 as set forth in the amino acid sequence of SEQ ID NO: 177, a CDR-H3 as set forth in the amino acid sequence of SEQ ID NO: 178, a CDR-L1 as set forth in in the amino acid sequence of SEQ ID NO: 179, a CDR-L2 as set forth in the amino acid sequence of SEQ ID NO: 180, and a CDR-L3 as set forth in the amino acid sequence of SEQ ID NO: 181, and
a second domain comprising an antibody which binds to an extracellular epitope of the human CD3ε chain.
|